On Apr. 8, 2020, Novavax announced it had identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavaxﾒ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavaxﾒ proprietary Matrix-Mﾙ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies.